GSK reports positive RSV vaccine data

Primary endpoints were met and no side effects were reported in a trial of GSK’s RSV vaccine.

Photo: Hannah Mckay/Reuters/Ritzau Scanpix

GSK, formerly Glaxosmithkline, has reported positive data from its RSV vaccine trial, Bloomberg News reports.

The media says that this is a boost for the firm, as it is preparing to split its Haleon user healthcare division into a separate unit.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs